U.S. gives full approval to 1st COVID-19 drug for young children



2:091 in 4 children develops ‘long COVID’ after infection: study

WATCH: 1 in 4 children develops ‘long COVID’ after infection: study – Mar 16, 2022

The U.S. drug regulator on Monday granted the first full approval for treating COVID-19 in children aged 28 days and older to Gilead Sciences Inc’s GILD.O drug remdesivir.

The move comes months after the agency expanded the drug’s emergency use authorization to also include children below 12 years of age weighing at least 3.5 kilograms.

Read more:

Canada changes COVID-19 border rules for unvaccinated, partially vaccinated kids

The Food and Drug Administration’s (FDA) decision makes the drug the first approved COVID-19 treatment for children less than 12 years of age, the agency said.

Trending Stories

Unvaccinated people increase risk of COVID-19 infection among vaccinated: new study

Judge holds Donald Trump in contempt for not complying with subpoena

The approval is applicable to children who are hospitalized, or have mild-to-moderate disease and are at high risk of severe COVID-19.

(Reporting by Manas Mishra in Bengaluru; Editing by Aditya Soni)

© 2022 Reuters